主管单位:中华人民共和国
国家卫生健康委员会
主办单位:中国医师协会
总编辑:杨秋
编辑部主任:吴翔宇
邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)
英文作者:Fan Xingxiu1 Guo Jianping2 Niu Haigang1
单位:1山西医科大学汾阳学院,汾阳032200;2山西省汾阳医院普外科,汾阳032200
英文单位:1Fenyang College of Shanxi Medical University Fenyang 032200 China; 2Department of General Surgery Fenyang Hospital in Shanxi Province Fenyang 032200 China
英文关键词:Triple-negativebreastcancer;Tumor-associatedmacrophages;Neoadjuvanttherapy
三阴性乳腺癌(TNBC)是乳腺癌中具有高度异质性的一种类型。由于其缺乏特异的治疗标志物,复发率、死亡率以及侵袭性均高于其他类型乳腺癌。近年来,肿瘤研究的焦点在于肿瘤微环境,肿瘤相关巨噬细胞(TAM)占乳腺癌间质细胞的50%以上,且是肿瘤微环境中最多的免疫细胞。目前关于TAM与肿瘤相关机制的大量研究发现,TAM在肿瘤发生发展中扮演重要角色,有望成为TNBC治疗及预后预测的生物标志物。本文对TAM在TNBC中的作用及潜在治疗策略进行综述。
Triple-negative breast cancer (TNBC) is a highly heterogeneous subtype of breast cancer. Due to its lack of specific treatment markers, its recurrence rate, mortality rate, and aggressiveness are all higher than other types of breast cancer. In recent years, the focus of tumor research has been on the tumor microenvironment, and tumor-associated macrophages (TAM) account for more than 50% of the stromal cells in breast cancer and are the most abundant immune cells in the tumor microenvironment. A large number of studies on the relationship between TAM and tumor-related mechanisms have found that TAM play an important role in tumor development and progression, making them a promising biomarker for TNBC treatment and prognosis prediction. This review summarizes the role of TAM in TNBC and potential treatment strategies.
copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址:www.chinamedicinej.com 京ICP备2020043099号-3
当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。